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Pulmonary embolism is a common condition with severe
repercussions. Massive PE causes hypotension, deﬁned as systolic
blood pressure <90 mmHg or a drop in systolic pressure
>40 mmHg in reference to the baseline value. PE without
hypotension is considered sub massive.11,17
Non-treated PE results in a 30% mortality rate. The mortality in
massive PE is higher (60%).1,3,6,14 Patients with massive PE require
intensive care admission. The treatment includes haemodynamic
support (ﬂuid replacement and vasoactive drugs), respiratory
support (intubation and mechanical ventilation), and anticoagu-
lants together with thrombolytics to accelerate the lysis of the
thrombus. In patients with massive PE in whom thrombolysis is
contraindicated or has failed, percutaneous or surgical embolec-
tomy is indicated. Likewise, if anticoagulation is contraindicated, a
vena cava ﬁlter should be considered.9
Despite the contraindications regarding this case (recent
surgery and thrombocytopenia), the patient was treated with
mechanical thrombectomy through a pulmonary artery catheter
together with intermediate doses of intra-arterial thrombolytics in
order to avoid embolization in the distal pulmonary bed. Although
the risk of bleeding was signiﬁcant, the outcome was favourable
and no signs of bleeding were observed.* Corresponding author at: Critical Care Center, Hospital de Sabadell, Corporacio´
Sanita`ria Parc Taulı´, Institut Universitari Parc Taulı´, C/Parc Taulı´, s/n, 08208
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A 17-year-old girl suffered multiple trauma after a 15 m fall. At
admission, her Glasgow Coma Scale was 15, she had no
neurological deﬁcit, and her ventilation and haemodynamics were
stable with sinus tachycardia (130 bpm). Body CT showed bilateral
hemopneumothorax with rib fractures, a fractured sternum, and
severe abdominal trauma with grade IV/V liver injury. It also
showed pancreatic and right adrenal laceration with hemoper-
itoneum. The patient also had several bone injuries such as right
ischiopubic fractures and transverse apophyses of L1 as well as
metaphyseal fractures of both radiuses.
After the initial evaluation, she developed severe haemody-
namic instability which required multiple transfusions and
urgent damage control surgery in which an abdominal packing
to control the diffuse bleeding was placed. The abdomen was
sealed and the patient was given 0.6 mg/30,000 IU of recombinant
activated factor VII (rFVIIa). After surgery, the patient developed a
new episode of instability due to the elevated intraabdominal
pressure. The surgery for abdominal compartmental syndrome
consisted of abdominal decompression and placing a vacuum-
assisted closure (VAC1) system. After transitory improvement
there was a new episode of instability. The patient presented clear
signs of bleeding through the VAC1 system, so multiple
transfusions of red blood cells, plasma and platelets as well as
vasoactive drugs (norepinephrine) were required. At this mo-
ment, she was transferred to our hospital for abdominal
angiography that showed no signs of active bleeding. The patient
improved and the administration of vasoactive drugs was
discontinued. Two days after the ﬁrst surgery, she underwent a
reintervention to remove the abdominal packing (removal before
48–72 h is recommended). During the surgery a hepatectomy
(segments VI and VII) was indicated because the liver was
damaged. There were no signs of bleeding and the abdomen ﬁnally
could be sealed.
Her chest trauma evolved favourably with bilateral pleural
drainage, and only low level Fi02 was needed to maintain
appropriate oxygen saturation.
Fig. 1. Computed tomography of the chest with massive pulmonary embolism. Fig. 2. Pulmonary arteriography with massive pulmonary embolism before
thrombolytic and mechanical treatment.
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showed progressive thrombocytopenia (minimal of 22  109/l),
and sudden patient-ventilator asynchrony with severe acute
respiratory failure (p02 68 with Fi02 0.8). The chest X-ray
showed no signiﬁcant changes. Echocardiography showed
marked dilation of the right ventricle with movement of the
septum to the left ventricle. PE was suspected and conﬁrmed at
chest CT (Fig. 1) The patient showed severe respiratory failure
and haemodynamic instability requiring high Fi02 (1) and to
begin norepinephrine and dobutamine infusions (0.7 and 10 mg/
kg/min respectively).
Given the patient’s severity and the contraindication for
endovenous thrombolysis due to the recent surgery and severe
thrombocytopenia, we proceeded with a mechanical thrombect-
omy through a 6F catheter and hydrophilic guide wire placed in the
pulmonary artery. A fragmentation catheter mediated and
repeated aspirations to remove the thrombus (Fig. 2) were then
performed. Pulmonary angiography showed severe proximal
bilateral ﬁlling defects that worsened after mechanical throm-
bectomy due to distal embolization of fragmented thrombi, so
intermediate doses (300,000 UI) of intra-arterial urokinase were
administered. This treatment provided clinical and radiological
improvement. A temporary inferior vena cava ﬁlter was placed,
although deep vein thrombosis was ruled out in favour of the
diagnosis of massive PE secondary to abdominal packing and the
administration of rFVIIa. The patient’s haemodynamics and
respiratory status improved during the following days, and
unfractioned heparin was administered in increasing doses. The
administration of vasoactive drugs was discontinued and the
patient was extubated 8 days after the PE episode, without
respiratory repercussions. The vena cava ﬁlter was later with-
drawn, and the patient was discharged, from the ICU, 15 days after
admission (Fig. 2).
3. Discussion
We present a case of a trauma patient who developed an early
massive PE after abdominal packing and rFVIIa administration.12The patient was managed with percutaneous embolectomy and
intra-arterial thrombolytics.
This case raises two main controversial topics: the ﬁrst one is if
rFVIIa administration could be a risk factor for PE development.
The second one is about, the best treatment of massive PE, in a
clinical situation with high bleeding risk.
The FDA-approved indications in the United States and Europe,
of rFVIIa, are for promoting haemostasis in haemophiliacs patients
as well as for treatment of congenital factor VII deﬁciency and
Glanzmann’s thrombasthenia.10 Also rFVIIa was investigated as a
haemostatic agent in bleeding conditions other than haemophilia
and numerous case reports, series, and small clinical trials have
reported the effective use of rFVIIa in a wide range of conditions
(off-label uses). Two multi-centre controlled trials of the use of
rFVIIa, in trauma patients, were published in 2005 and 2006. There
were no differences in adverse events, such as thromboembolism
or mortality, between the treatment groups in either study.2 In a
2008 meta-analysis of 22 randomized controlled trials of rFVIIa in
3184 patients concluded that the use of rFVIIa did not signiﬁcantly
decrease mortality but it did increase the incidence of thrombo-
embolic events.7 Arterial and venous thrombotic and thromboem-
bolic events, some fatal, following administration of factor VIIa
have been reported during post marketing surveillance (1–9.8%).
Most of these complications have been associated with off-label
use. Events included thromboembolic cerebrovascular accidents,
acute myocardial infarction, arterial thrombosis, pulmonary
embolism, venous thrombosis and clotted access devices. Cautious
use is recommended in patients with an increased risk of
thromboembolic complications (e.g., liver disease, postoperative
immobilization, elderly patients. . .).
In the off-label uses it is recommended for drugs to be a last
resort (level of evidence 2C). The optimal dose and schedule are not
known with certainty but there are several studies showing risk of
arterial thrombosis with increasing doses, so an initial dose of
90 mg/kg would seem most appropriate.
For the treatment of pulmonary embolism, as stipulated in
clinical guidelines,17 our patient required high oxygen concentra-
tion and ﬂuid replacement therapy. Given the lack of improvement
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vasopressors were administered (level of evidence 1B): norepi-
nephrine (level of evidence 2C) combined with dobutamine.
PE requires initial short-term therapy with a rapid-onset
anticoagulant, but it was not used due to the patient’s contra-
indications (severe thrombocytopenia and recent surgery, 48 h
earlier). The presence of an experienced multidisciplinary team
and an interventional radiology unit at our hospital made
percutaneous mechanical thrombectomy and inferior vena cava
ﬁlter placement a viable treatment option (level of evidence 2C).
In massive PE, thrombolytic treatment (urokinase, streptoki-
nase, or alteplase) is indicated together with anticoagulation9 to
accelerate the lysis of the thrombus (level of evidence 2B).
The most recent meta-analyses showed an improvement in
mortality rates when using thrombolytics instead of administrat-
ing only anticoagulants.5,18
In this case, given the high percentage of poor outcomes for
mechanical thrombectomy due to peripheral embolisms and the
severity of our patient, it was decided to add thrombolysis with
intermediate doses of urokinase for mechanical thrombect-
omy.4,8,13,15,16 Our patient’s outcome was good and she had no
hemorrhagic complications. To our knowledge, this is the ﬁrst
reported case with concomitant mechanical thrombectomy,
arterial thrombolysis and inferior vena cava ﬁlter placement.
4. Conclusions
This case illustrates that although massive PE is both a fatal
disease and a medical emergency, an early diagnosis and intensive
combined treatment can be life-saving. This treatment should take
in account patient’s severity, in addition of indications and
contraindications of each one of these therapeutic possibilities.
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